Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micrologix biotech -- Ignore unavailable to you. Want to Upgrade?

To: checkmate who wrote (483)	4/27/1999 6:16:00 PM
From: Robert Ling	Read Replies (1) \| Respond to of 792

good news.... Micrologix successfully completes Phase I clinical trial for the prevention of bloodstream infections VANCOUVER, April 27 /CNW/ - Micrologix Biotech Inc. Trading Symbol: MBI (TSE/VSE) MGIXF (US over the counter) Micrologix Biotech Inc. is pleased to announce that it has successfully completed a two-part Phase I human clinical trial of MBI 226, its lead Bactolysin drug candidate for preventing bloodstream infections in patients undergoing central venous catheterization. The study showed that MBI 226 is safe and well tolerated, eliminates 99.9% of bacteria commonly found on the skin and prevents bacterial growth on catheters. We will present these results to the United States FDA and intend to initiate Phase II clinical trials in the second half of this year. The Centers for Disease Control and Prevention in Atlanta estimate that in the US alone, 200,000 hospital patients contract bloodstream infections each year. Central venous catheters (CVCs) cause more than 90% of these infections, and on average, infected patients spend an additional 6.5 days in intensive care at a cost of $29,000. The associated mortality rate is high: up to 50,000 patients die annually from these bloodstream infections. As a result of the serious morbidity and mortality rates associated with these infections, the FDA announced in September 1998 that it is placing a high priority on supporting the development and approval of drugs to prevent and treat bloodstream infections. More effective means of prevention or treatment would save many lives and billions of dollars in health care costs in North America alone.

To: checkmate who wrote (483)	4/27/1999 7:53:00 PM
From: Carter Berezay	Read Replies (1) \| Respond to of 792

Checkmate: I hope we never hear from you again! How's your beloved Sepracor doing? Down under $100 from about $133, about 25% down. MBI won't do a bad deal, that's why. Carter B.

To: checkmate who wrote (483)	4/27/1999 9:42:00 PM
From: Larry G.	Read Replies (1) \| Respond to of 792

Hi checkmate, It is good to hear from you. I sorry but I must disagree with your appraisal of MBI. MBI is a very good company. The sky is the limit. It is a long term hold and it is possible to reach $100 in 5 years and no limit to it's potential. From $2.00 to $100 is 50 times or 5000% in 5 years. Only time will prove us wrong but I think it will be some where in between your and my guess. I think it will be closer to me than you. I put my money where my mouth is. This is my biggest position. If it hit $10.00 I will be happy but I will not sell. I do not see why you waste your time telling us why MBI is such a bad investment. Why waste your time? Why don't you look for a good stock?